TY - JOUR
T1 - The prognostic role of tumor associated macrophages in squamous cell carcinoma of the head and neck
T2 - A systematic review and meta-analysis
AU - Bisheshar, Sangeeta K
AU - van der Kamp, Martine F
AU - de Ruiter, Emma J
AU - Ruiter, Lilian N
AU - van der Vegt, Bert
AU - Breimer, Gerben E
AU - Willems, Stefan M
N1 - Publisher Copyright:
© 2022 The Author(s)
PY - 2022/12
Y1 - 2022/12
N2 - Head and neck squamous cell carcinoma (HNSCC) is an immunogenic cancer type, and tumor associated macrophages (TAMs) are a major component of the tumor microenvironment (TME). In this systematic review and meta-analysis, studies assessing tumor infiltration with CD68+, iNOS+, HLA-DR+, CD11b+, CD163+, CD206+, and CD204+TAMs were included, and correlation to survival hazard was studied. A low number of CD68+TAMs correlated to better overall survival (OS) in multivariate analysis (HR 1.36 95 %CI (1.07-1.72) P = .01). CD68+TAMs did not correlate to disease free survival (DFS), disease specific survival (DSS), progression free survival (PFS), or recurrence free survival (RFS). A low number of CD163+TAMs correlated to better OS in uni- and multivariate analysis (resp. HR 2.65 95 %CI (1.57-4.46) P = .01 and HR 2.42 95 %CI (1.72-3.41) P < .001). A low number of CD163+TAMs also correlated to better DFS and PFS, whereas a low number of CD204+TAMs only correlated to PFS. While IHC analysis of pan macrophage marker CD68 and M2-like marker CD163 both show prognostic utility in OS, CD163 is a stronger prognosticator, as indicated by multivariate meta-analysis. CD163+TAMs also correlate to DFS and PFS; outcomes that are more relevant to patients, thus showing promising results for future clinical implementation.
AB - Head and neck squamous cell carcinoma (HNSCC) is an immunogenic cancer type, and tumor associated macrophages (TAMs) are a major component of the tumor microenvironment (TME). In this systematic review and meta-analysis, studies assessing tumor infiltration with CD68+, iNOS+, HLA-DR+, CD11b+, CD163+, CD206+, and CD204+TAMs were included, and correlation to survival hazard was studied. A low number of CD68+TAMs correlated to better overall survival (OS) in multivariate analysis (HR 1.36 95 %CI (1.07-1.72) P = .01). CD68+TAMs did not correlate to disease free survival (DFS), disease specific survival (DSS), progression free survival (PFS), or recurrence free survival (RFS). A low number of CD163+TAMs correlated to better OS in uni- and multivariate analysis (resp. HR 2.65 95 %CI (1.57-4.46) P = .01 and HR 2.42 95 %CI (1.72-3.41) P < .001). A low number of CD163+TAMs also correlated to better DFS and PFS, whereas a low number of CD204+TAMs only correlated to PFS. While IHC analysis of pan macrophage marker CD68 and M2-like marker CD163 both show prognostic utility in OS, CD163 is a stronger prognosticator, as indicated by multivariate meta-analysis. CD163+TAMs also correlate to DFS and PFS; outcomes that are more relevant to patients, thus showing promising results for future clinical implementation.
KW - CD163
KW - CD204
KW - CD206
KW - CD68
KW - Disease free survival (DFS)
KW - Disease specific survival (DSS)
KW - Head and Neck Squamous Cell Carcinoma (HNSCC)
KW - Locoregional control (LRC)
KW - Overall survival (OS)
KW - Progression free survival (PFS)
KW - Recurrence free survival (RFS)
KW - Tumor associated macrophages (TAMs)
UR - https://www.scopus.com/pages/publications/85141275738
U2 - 10.1016/j.oraloncology.2022.106227
DO - 10.1016/j.oraloncology.2022.106227
M3 - Review article
C2 - 36335818
SN - 1368-8375
VL - 135
SP - 1
EP - 9
JO - Oral Oncology
JF - Oral Oncology
M1 - 106227
ER -